Oxaliplatin in the adjuvant treatment of colon cancer

奥沙利铂 结直肠癌 佐剂 医学 肿瘤科 内科学 癌症
作者
Mary Kay Barton
出处
期刊:CA: A Cancer Journal for Clinicians [Wiley]
卷期号:62 (1): 3-4 被引量:9
标识
DOI:10.3322/caac.21131
摘要

Updated results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial evaluating the addition of oxaliplatin to fluorouracil (5-FU) and leucovorin in the adjuvant treatment of patients with colon cancer confirmed previous findings of a strong disease-free survival (DFS) advantage. The findings, however, showed no advantage in overall survival (OS) for the entire cohort. Greg Yothers, PhD, research assistant professor in biostatistics at the University of Pittsburgh and associate director of the NSABP Biostatistical Center in Pittsburgh, Pennsylvania, and colleagues recently published this first report of OS and updated DFS data, as well as an exploratory analysis of patient subsets of the C-07 trial (J Clin Oncol [published online ahead of print August 22, 2011]. doi: 10.1200/JCO. 2011. 36.4539). The addition of oxaliplatin to 5-FU and leucovorin has been established as a standard of care for the adjuvant treatment of patients with colon cancer mainly by 2 phase 3 trials: one titled “Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer” (the NSABP C-07 trial) and another titled “The Multicenter International Study of Oxaliplatin/5FU/Leucovorin in the Adjuvant Treatment of Colon Cancer” (MOSAIC) (N Engl J Med. 2004; 350:2343-2351). “This updated report confirms the durability of the [DFS] effect of oxaliplatin as originally reported for the NSABP C-07 and MOSAIC trials,” Dr. Yothers says. Questions remain, however, as to patient selection for oxaliplatin in the adjuvant setting. DFS was significantly increased in both trials, and the OS in the MOSAIC trial showed a benefit for the entire cohort. However, on further analysis, the authors of the MOSAIC trial concluded that only patients with stage III disease experienced the OS benefit (J Clin Oncol. 2009;27:3109-3116). A more recent phase 3 study comparing 5-FU and leucovorin with oxaliplatin and capecitabine (XELOX) for the adjuvant treatment of colon cancer has also been reported, with a clear DFS benefit noted with the oxaliplatin regimen (J Clin Oncol. 2011;29:1465-1471). After 5 years, OS was not found to be increased in this trial, but longer follow-up is planned. In the NSABP C-07 trial, 2409 patients with resected stage II (29%) or stage III colon cancer were randomized to receive a bolus 5-FU and leucovorin regimen given for 6 consecutive weeks with 2 weeks of rest (FULV) or the same regimen plus oxaliplatin given on days 1, 15, and 29 of each cycle (FLOX). Three 8-week cycles were planned. (In the MOSAIC trial, 5-FU was given as a continuous infusion.) Demographics and disease characteristics were well balanced between the 2 study arms. There was a nonsignificant trend toward improved OS noted in the FLOX arm for the entire study population, with a hazard ratio (HR) for FLOX versus FULV of 0.88, corresponding to a 12% relative reduction in the risk of death. OS estimates at 5 years were 78.4% for the FULV regimen and 80.2% for the FLOX regimen. The chemical structure of oxaliplatin. DFS was found to be significantly better in the FLOX group (P = .002). The HR for FLOX versus FULV was 0.82, an 18% relative reduction in the risk of disease recurrence or death. Overall DFS estimates at 5 years were 64.2% for the FULV regimen and 69.4% for the FLOX regimen. Multivariate modeling was performed with the following factors to assess benefits for specific subgroups: chemotherapy regimen, age (< 70 years vs ≥ 70 years), gender, number of positive lymph nodes (0 vs 1-3 vs > 3), depth of invasion, and location of the tumor (right vs left). In this analysis, only the age-treatment regimen interaction was significantly different between groups, suggesting that the addition of oxaliplatin in patients aged younger than 70 years was different from those aged 70 years or older. Because of this significant interaction, the researchers analyzed outcomes separately by age group. OS was found to be significantly improved with FLOX versus FULV for patients aged younger than 70 years (HR, 0.80; P = .013). The 5-year OS estimates were 78.8% for the FULV regimen compared with 81.8% for the FLOX regimen. No significant difference was noted between treatment groups for those patients aged 70 years or older, but the OS rate was 4.7% worse with FLOX in the older age group. DFS results showed a trend toward a difference with regard to the effect of oxaliplatin in patients aged younger than 70 years compared with those aged 70 years or older, but the interaction was not significant. Patients aged 70 years or older in the FULV arm had a grade 4 or 5 toxicity rate of 13%, while those in the FLOX arm had a grade 4 or 5 toxicity rate of 20%. In the patients in the younger age group, these rates were 9% and 10%, respectively, for the FULV and FLOX regimens. The cumulative dose of oxaliplatin was approximately 25% lower in the older age groups, but dose intensity was similar between the age groups, suggesting that older patients more often withdrew from oxaliplatin therapy before the planned 6 months of treatment. “This update of the NSABP C-07 trial does not change clinical practice,” says Axel Grothey, MD, professor of oncology at the Mayo Clinic in Rochester, Minnesota. “The adjuvant treatment of colorectal cancer in the United States is dominated by the oxaliplatin-containing regimens, though this update and other recent data questions the use of oxaliplatin in older patients and it has never shown a survival benefit in stage II patients.” The NSABP C-07 trial showed only a trend toward improved OS with oxaliplatin, with a HR of 0.88 (P = .08). This finding is not very different from the MOSAIC trial's statistically significant HR of 0.84 for OS, favoring oxaliplatin. Taken together, the 2 trials show an approximately 15% reduction in the hazard of death for all participants. The NSABP C-07 trial also demonstrated a significant OS advantage in the younger age group but not in the patients aged 70 years and older. “There is some evidence from NSABP C-07 that patients over age 70 experienced poorer OS and DFS outcomes when oxaliplatin was added to a 5-FU chemotherapy regimen as compared to patients treated with fluoropyrimidine therapy alone,” Dr. Yothers says. The authors suggest that when making treatment decisions regarding the addition of oxaliplatin to 5-FU and leucovorin for the adjuvant treatment of colon cancer, age should be just one of the factors considered. “We do not encourage the use of chronologic age 70 as a rigid threshold for a decision to use oxaliplatin. The patient's overall state of health should be considered, and frail patients under 70 should perhaps not get oxaliplatin while robust patients over age 70 perhaps should get it,” Dr. Yothers says. The authors also noted in the study that previous trials have shown that elderly patients with colon cancer benefit from adjuvant 5-FU and leucovorin (N Engl J Med. 2001;345:1091-1097). According to Dr. Grothey, once the decision is made that a patient should receive adjuvant chemotherapy for stage III colon cancer, oxaliplatin-containing regimens are standard unless the patient is not thought to be able to tolerate it. Other issues such as better patient selection for adjuvant therapy using molecular testing and potentially using shorter durations of therapy are currently being addressed in numerous clinical trials, he says. Dr. Grothey says he hopes this ongoing work will help achieve a more individualized approach, causing less toxicity and maximizing benefit.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
巴音布鲁克完成签到 ,获得积分10
刚刚
2秒前
devilito发布了新的文献求助10
2秒前
2秒前
hzy完成签到 ,获得积分10
3秒前
伊申士发布了新的文献求助10
3秒前
4秒前
秋风的应助被Reiker采纳,获得20
4秒前
Owen的应助被Reiker采纳,获得10
4秒前
meiguohuo发布了新的文献求助10
5秒前
6秒前
6秒前
lxy完成签到,获得积分10
8秒前
真实的灵安完成签到,获得积分10
8秒前
斯文败类的应助被hyy采纳,获得10
9秒前
9秒前
所所的应助被lcj1014采纳,获得10
9秒前
LeoLee完成签到,获得积分10
9秒前
辞旧完成签到,获得积分10
10秒前
10秒前
10秒前
11秒前
mmmxuuuuan完成签到,获得积分10
12秒前
ding的应助被TTTYL采纳,获得10
12秒前
领导范儿的应助被siru采纳,获得10
12秒前
13秒前
直率的大楚完成签到,获得积分10
13秒前
强健的碧琴完成签到,获得积分10
13秒前
15秒前
mihhhhh完成签到,获得积分10
15秒前
完美世界的应助被绵绵采纳,获得10
16秒前
赘婿的应助被igiss采纳,获得10
16秒前
长庚发布了新的文献求助10
17秒前
18秒前
18秒前
19秒前
稳重念文完成签到,获得积分10
20秒前
20秒前
hmj完成签到,获得积分10
20秒前
温暖的如冰完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177901
求助须知:如何正确求助?哪些是违规求助? 9568676
关于积分的说明 21800345
捐赠科研通 7772540
什么是DOI,文献DOI怎么找? 3432548
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478085